Last mentioned: 6d ago
Settlement Reached
Both companies announce an end to litigation and the start of a strategic collaboration.
Supply Stabilization
Novo Nordisk increases supply of branded Wegovy, challenging the legal basis for compounding.
Hims Enters Market
Hims & Hers launches its compounded semaglutide offering at a lower price point.
Litigation Begins
Novo Nordisk starts filing lawsuits against compounding pharmacies for IP infringement.
Hims & Hers Health shares skyrocketed 41% following a strategic agreement with Novo Nordisk to distribute branded GLP-1 medications, including Ozempic, directly through its telehealth platform. The deal effectively ends a high-stakes patent dispute and transitions the company away from controversial compounded formulations toward FDA-approved branded therapies.
Hims & Hers Health and Novo Nordisk have settled their legal dispute regarding compounded weight loss medications, transitioning into a strategic collaboration. This agreement marks a significant shift in the GLP-1 market, moving from litigation to a partnership that could broaden access to semaglutide treatments.